Short- and long-term effects of tactile massage on salivary cortisol concentrations in Parkinson’s disease: a randomised controlled pilot study

BMC Complementary and Alternative Medicine

Johan Lökk⁴  Håkan Sandbjörk¹  Ulla Birgitta Lennartsson¹  Miriam Carlsson⁶  Birgitta Bringer³  Gunnar Hallgren¹  Per-Arne Fall³  Paulina Backström⁶  Lena Andersson¹  Lena Andersson⁶  Laila Robertsson⁶  Birgitta Larsson¹  Astrid Borg⁵  Örjan Skogar⁴  Carl-Johan Törnhage² 

[1] Department of Neurology, Skaraborg Hospital, Skovde, Sweden;Department of Pediatrics, Skaraborg Hospital, SE-541 85 Skovde, Sweden;Department of Geriatrics, University Hospital, Linkoping, Sweden;Institution of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden;Swedish Parkinson Foundation, Stockholm, Sweden;Department of Geriatrics, Ryhov Hospital, Jönkoping, Sweden

关键词: Stress;    Parkinson disease;    Massage;    Cortisol;    Complementary therapies;    Circadian rhythm;   

Others  :  1220439
DOI  :  10.1186/1472-6882-13-357

 received in 2012-09-25, accepted in 2013-12-05,  发布年份 2013

【 摘 要 】

Background

Parkinson’s disease (PD) is a chronic neurodegenerative disorder with limited knowledge about the normal function and effects of non-pharmacological therapies on the hypothalamic-pituitary-adrenal (HPA) axis. The aim of the study was to analyse the basal diurnal and total secretion of salivary cortisol in short- and long-term aspects of tactile massage (TM)_.

Methods

Design: Prospective, Controlled and Randomised Multicentre Trial.

Setting and interventions: Forty-five women and men, aged 50–79 years, were recruited. Twenty-nine of them were blindly randomised to tactile massage (TM) and 16 of them to the control group, rest to music (RTM). Ten interventions were given during 8 weeks followed by a 26 weeks of follow up. Salivary cortisol was collected at 8 am, 1 pm, 8 pm, and 8 am the next day, on five occasions. With the first and eighth interventions, it was collected immediately before and after intervention.

Main outcome measures: The primary aim was to assess and compare cortisol concentrations before and immediately after intervention and also during the follow-up period. The secondary aim was to assess the impact of age, gender, body mass index (BMI), duration and severity of PD, effects of interventional time-point of the day, and levodopa doses on cortisol concentration.

Results

The median cortisol concentrations for all participants were 16.0, 5.8, 2.8, and 14.0 nmol/L at baseline, later reproduced four times without significant differences. Cortisol concentrations decreased significantly after TM intervention but no change in diurnal salivary cortisol pattern was found. The findings of reduced salivary cortisol concentrations immediately after the interventions are in agreement with previous studies. However, there was no significant difference between the TM and control groups. There were no significant correlations between cortisol concentrations and age, gender, BMI, time-point for intervention, time interval between anti-parkinson pharmacy intake and sampling, levodopa doses, duration, or severity of PD.

Conclusions

Diurnal salivary cortisol rhythm was normal. Salivary cortisol concentrations were significantly reduced after the TM intervention and after RTM, but there were no significant differences between the groups and no sustained long-term effect. No associations were seen between salivary cortisol concentration and clinical and/or pharmacological characteristics.

Trial registration

ClinicalTrial.gov, NCT01734876 and FoU Sweden 108881.

【 授权许可】

   
2013 Törnhage et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Bruguerolle B, Simon N: Biologic rhythms and Parkinson’s disease: a chronopharmacologic approach to considering fluctuations in function. Clin Neuropharmacol 2002, 25(4):194-201.
• [2]Politis M, Wu K, Molloy S, GB P, Chaudhuri KR, Piccini P: Parkinson’s disease symptoms: the patient’s perspective. Mov Disord 2010, 25(11):1646-1651. doi:10.1002/mds.23135
• [3]Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Ch’erif AA: Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002, 59(3):408-413.
• [4]Simuni T, Sethi K: Nonmotor manifestations of Parkinson’s disease. Ann Neurol 2008, 64(Suppl 2):S65-S80. doi:10.1002/ana.21472
• [5]Terriff DL, Williams JV, Patten SB, Lavorato DH, Bulloch AG: Patterns of disability, care needs, and quality of life of people with Parkinson’s disease in a general population sample. Parkinsonism Relat Disord 2012. doi:10.1016/j.parkreldis.2012.03.026
• [6]Bainbridge JL, Ruscin JM: Challenges of treatment adherence in older patients with Parkinson’s disease. Drugs Aging 2009, 26(2):145-155.
• [7]Lokk J, Nilsson M: Frequency, type and factors associated with the use of complementary and alternative medicine in patients with Parkinson’s disease at a neurological outpatient clinic. Parkinsonism Relat Disord 16(8):540-544. doi:10.1016/j.parkreldis.2010.06.007
• [8]Skogar O, Fall PA, Hallgren G, Lokk J, Bringer B, Carlsson M, Lennartsson U, Sandbjork H, Törnhage C-J: Diurnal salivary cortisol concentrations in Parkinson’s disease: increased total secretion and morning cortisol concentrations. Int J Gen Med. 2011, 4:561-569. doi:10.2147/ijgm.s20875
• [9]Barker ET, Greenberg JS, Seltzer MM, Almeida DM: Daily stress and cortisol patterns in parents of adult children with a serious mental illness. Health Psychol 2012, 31(1):130-134. doi:10.1037/a0025325
• [10]Murphy L, Denis R, Ward CP, Tartar JL: Academic stress differentially influences perceived stress, salivary cortisol, and immunoglobulin-A in undergraduate students. Stress 2010, 13(4):365-370. doi:10.3109/10253891003615473
• [11]Vining RF, McGinley RA, Maksvytis JJ, Ho KY: Salivary cortisol: a better measure of adrenal cortical function than serum cortisol. Ann Clin Biochem 1983, 20(Pt 6):329-335.
• [12]Port K: Serum and saliva cortisol responses and blood lactate accumulation during incremental exercise testing. Int J Sports Med 1991, 12(5):490-494.
• [13]Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I: Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging 1997, 18(3):285-289.
• [14]Field TM: Massage therapy effects. Am Psychol 1998, 53(12):1270-1281.
• [15]Schrag A, Jahanshahi M, Quinn N: How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000, 15(6):1112-1118.
• [16]Sprigg N, Gray LJ, Bath PM, Christensen H, De Deyn PP, Leys D, O’Neill D, Ringelstein EB: Quality of life after ischemic stroke varies in Western Countries: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). J Stroke Cerebrovasc Dis 2012, 21(7):587-593.
• [17]Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ: Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 2002, 17(5):867-876.
• [18]Schulz KF, Altman DG, Moher D, and the CONSORT Group: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010, 8:18. doi:10.1186/1741-7015-8-18
• [19]Törnhage C-J: Salivary cortisol for assessment of hypothalamic-pituitary-adrenal axis function. Neuroimmunomodulation 2009, 16(5):284-289. doi:10.1159/000216186
• [20]Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH: Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 2003, 28(7):916-931.
• [21]Fekedulegn DB, Andrew ME, Burchfiel CM, Violanti JM, Hartley TA, Charles LE, Miller DB: Area under the curve and other summary indicators of repeated waking cortisol measurements. Psychosom Med 2007, 69(7):651-659. doi:10.1097/PSY.0b013e31814c405c
• [22]Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE: Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010, 25(15):2649-2653. doi:10.1002/mds.23429
• [23]Stringer J, Swindell R, Dennis M: Massage in patients undergoing intensive chemotherapy reduces serum cortisol and prolactin. Psychooncology 2008, 17(10):102431. doi:10.1002/pon.1331
• [24]Hernandez-Reif : Parkinsons disease symptoms are differentially affected by massage therapy versus progressive muscle relaxation. J Bodyw Mov Therapy 2002, 3(6):177-182.
• [25]Field T, Hernandez-Reif M, Diego M, Schanberg S, Kuhn C: Cortisol decreases and serotonin and dopamine increase following massage therapy. Int J Neurosci 2005, 115(10):1397-1413. doi:10.1080/00207450590956459
• [26]Moraska A, Pollini RA, Boulanger K, Brooks MZ, Teitlebaum L: Physiological adjustments to stress measures following massage therapy: a review of the literature. Evid Based Complement Alternat Med 2010, 7(4):409-418. doi:10.1093/ecam/nen029
• [27]Skogar O, Borg A, Larsson B, Robertsson L, Andersson L, Andersson L, Backstrom P, Fall P-A, Hallgren G, Bringer B, Carlsson M, Lennartsson U, Sandbjork H, Lökk J, Törnhage C-J: “Effects of tactile touch on pain, sleep and health related quality of life in Parkinson’s disease with chronic pain” a randomized, controlled and prospective study. European J Integ Med 2013, 5:141-152.
• [28]Wormnes B, Dundas I, Manger T: Response to placebo can potentiate medical treatment. Be aware-and influence-the patient’s attitude to the treatment. lakartidningen 2008 December 10-16, 105(50):3638-3642. (0023–7205 (Print))